| Name | Title | Contact Details |
|---|
IQUW is a global specialty (re) insurer at Lloyds (syndicate 1856), underwriting complex risks and developing a new way to combine data, intelligent automation and human expertise to make smart decisions, fast. Led by a team of expert underwriters, we underwrite a diverse, multi-line product portfolio including Cargo, Cyber, Delegated Authority Property, D&F Property, D&O, Energy, Financial Institutions, Marine and Energy Liability, Political Violence, Terrorism and War, Property Treaty and Specialty Reinsurance. And because we are a Lloyds syndicate, all our policies come with an A+ rating from Lloyds. To connect with a member of the IQUW team, visit IQUW.com or to visit, you can find us at our HQ in 30 Fenchurch Street, London or at Box 64, 137 and 221 at Lloyds.
We are a full service independent insurance brokerage firm. We have access to numerous national and regional carriers for personal and commercial product solutions for our clients. In addition to every day insurance solutions, our expanded markets enable us access to companies that specialize in retirement solutions. With over 15 years of advising our clients on risk management and insurance, we are able to confidently work with a young working professional just starting out, or the established high net worth family or closely held business with numerous needs. We leverage technology to make transitions seamless and our agency and carriers accessible beyond traditional office hours.
Palmer & Cay is a specialty commercial insurance and employee benefits brokerage and consulting firm. We specialize in industry niches with complex risks and extensive service needs, delivering high value services to clients on a worldwide basis. Our highly synchronized teams bring deep experience and strategic talents to each clients needs. Our focus is on middle market to large corporate clients, delivering Property & Casualty and Employee Benefits consulting & brokerage services, including risk analysis, claims consulting, program design, marketing and administration, and risk control. When losses occur, we surround our clients with intense claim advocacy services. Building upon a culture that was started nearly 150 years ago, we understood then, and today still believe, that people are what make an organization successful. To deliver on our promise to consistently deliver "exceptional client service", we know we have to attract the best, most passionate, and technical people in our business. Combining this fundamental approach with a culture where the client is at the center of everything we do allows us to create extraordinary results for our clients.
ZEA manufactures plant biologics for pharmaceutical uses providing wellness to the world. At ZEA, we are uprooting medicine by growing plants and using our proprietary technology to produce medicinal plant products and we offer superior data analytics in what is a $400 billion dollar market.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.